PureTech: Notice of Results
March 15 2021 - 2:00AM
Business Wire
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company") plans to publish its annual report and financial results
on Thursday, April 15, 2021 at 2:00 AM EDT / 7:00 AM BST. The
report will include the Company’s financial results for the year
ended December 31, 2020 as well as its cash balance for the first
quarter ending March 31, 2021. PureTech also plans to provide an
overview of progress across its Wholly Owned Pipeline and Founded
Entities in addition to the Company’s approach to environmental,
social and governance (ESG) practices.
A presentation and conference call for analysts will take place
at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a
webcast of the presentation will be available on the Company's
website at
https://investors.puretechhealth.com/events-presentations.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
as of the date of PureTech's most recently filed Registration
Statement on Form 20-F, was comprised of 24 therapeutics and
therapeutic candidates, including two that have received FDA
clearance and European marketing authorization. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our therapeutic candidates and those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210315005139/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
U.S. media Stephanie Simon +1 617 581 9333
stephanie@tenbridgecommunications.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024